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Noninvasive imaging of atherosclerosis could potentially move patient management towards individualized triage, treatment, and
followup. The newly introduced combined positron emission tomography (PET) and magnetic resonance imaging (MRI) system
could emerge as a key player in this context. Both PET and MRI have previously been used for imaging plaque morphology and
function: however, the combination of the twomethodsmay offer new synergistic opportunities. Here, wewill give a short summary
of current relevant clinical applications of PET and MRI in the setting of atherosclerosis. Additionally, our initial experiences with
simultaneous PET/MRI for atherosclerosis imaging are presented. Finally, future potential vascular applications exploiting the
unique combination of PET and MRI will be discussed.
1. Introduction
Molecular imaging can be defined as noninvasive visual-
ization and quantification of distinct molecular pathways.
Important features of molecular imaging are the ability
to target a molecular process in living organisms without
perturbing them. Both positron emission tomography (PET)
and magnetic resonance imaging (MRI) are classic methods
used for molecular imaging.
Atherosclerosis is traditionally assessed using luminal
stenosis by anatomical imaging such as angiography or
ultrasound. However, atherosclerosis is now recognized as
a systemic degenerative inflammatory vascular disease that
develops over decades, with a long subclinical period. Post-
mortem analyses have shown that most fatal vascular events
originate from nonstenotic atherosclerotic lesions [1], and
about half of all patients who die from coronary heart disease
have no prior diagnosis or symptoms of cardiac disease
[2]. Despite this fact, screening asymptomatic adults for
cardiovascular risk by imaging is considered inappropriate in
most cases by current guidelines [3].
The concept of the vulnerable plaque is a hallmark in
atherosclerosis. The vulnerable atherosclerotic plaques are
those with a high short-term risk of rupture and thrombosis.
The vulnerability of a plaque is characterized by a number of
factors like a thin, collagen-poor fibrous cap, a large necrotic
core, and abundant macrophages in the cap, whereas the
luminal protrusion is not a marker of vulnerability [4].
The current goal in noninvasive imaging is to identify vul-
nerable atherosclerotic plaques that may subsequently lead
to myocardial infarction or stroke. This identification could
lead to more optimal and individualized risk stratification
and thereby enabling personalized therapy.
The aim of this review is to give a summary of current
relevant clinical applications of PET and MRI in the setting
of atherosclerosis and to discuss potential future uses of the
newly introduced combined PET/MRI system.
2. Why Hybrid Imaging with PET and MRI?
A state-of-the-art MRI scanner offers the ability to per-
form both anatomical and functional examinations. The
atherosclerotic plaque components can be differentiated
using dedicated imaging sequences (Figure 1). T1-, T2-, and
proton density weighted imaging of carotid plaques allows for
identification of the lipid-rich necrotic core, calcification, and
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Figure 1: Example of multisequence MRI of a plaque in the right carotid artery (arrow). Each column shows three slices from the right
common carotid artery (top row) to the internal carotid artery (bottom row). The nonstenotic left coronary artery is shown for comparison
(arrowhead). Four different MR sequences are shown (T1 weighted, T2 weighted, proton density weighting, and time-of-flight angiography).
intraplaque hemorrhage. The high spatial resolution of MRI
even allows for identification and assessment of the fibrous
cap.One study published as early as 2002 included 60 patients
scheduled for carotid endarterectomy. The carotid arteries
were imaged in vivo with a 1.5-T scanner (time of flight
and T1-, PD-, and T2-weighted). The plaque classification
from this multisequence MRI showed good agreement with
the American Heart Association classifications from the
subsequent histological examination (Cohen’s kappa of 0.74)
[5]. Since then, the imaging technique has been improved by
optimization of the image sequences used, the introduction
of new imaging sequences, and increased magnetic field
strength in the MRI system. The fibrous cap is a major
contributor to the vulnerability of the plaque. The feasibility
of fibrous cap visualization by MRI in the carotid artery
is well established [6, 7], and fibrous cap rupture is asso-
ciated with cerebrovascular symptoms in both prospective
and cross-sectional studies [8, 9]. Neoangiogenesis in the
atherosclerotic plaque is also considered a hallmark of the
unstable plaque. Some studies indicate that dynamic contrast
enhancedMRI utilizing gadolinium-based extracellular con-
trast agents can be used to assess microvessel density in the
plaques [10].
MRI for plaque characterization in the coronary arteries
is technically more challenging than carotid plaques due to
cardiac and respiratory motion of the often small tortuous
vessels. Several methods are under development to deal
with these challenges. Some studies have in fact shown that
positive remodeling and intracoronary thrombus detection is
feasible in the coronary arteries [11, 12].
Molecular imaging with MRI is also possible using
specific contrast agents that allow for visualization of pro-
cesses in the atherosclerotic plaque at the molecular level.
Target specific MRI contrast agents are typically based on
paramagnetic gadolinium or iron oxide. Clinical studies have
demonstrated uptake of small iron oxide (USPIO) particles
in carotid plaques and the uptake was found to correspond
to areas of macrophage infiltration [13]. One study has even
used USPIO-enhanced carotid MRI to assess the therapeutic
response of short term aggressive lipid lower therapy [14].
Fibrin is another molecular target of MRI utilizing a fibrin-
specific gadolinium-based contrast agent.This agent has been
used in a few clinical studies for thrombi detection [15].
A number of other target specific MRI contrast agents for
imaging atherosclerosis are currently being tested in animal
models (review in [16]).
It is relevant in this context to consider what PET can
add to the “MRI-one-stop-shop.” Clinical PET has a spatial
resolution around 3mm at best and can thus in no way
compete with the spatial resolution of MRI. PET is based on
photon emission from positron emitting radioactive tracers
and does not contain anatomical information. Thus, PET
cannot be used to image morphological components of the
plaque. PET, however, is a sublime technique for molecular
imaging. Molecular imaging with MRI has a limited sensi-
tivity typically in the micromolar range, whereas a typical
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Figure 2: Example of vascular simultaneous FDG-PET/MRI from porcine model. The abdominal aorta is outlined in green (reproduced
from [18] with permission from the editor).
clinical PET scanner can detect concentrations in nano-
to picomoles per liter. This sensitivity, however, is lower
in plaque imaging since the plaque size is near the spatial
resolution of the system and thus subject to signal loss by
partial volume effects.
PET is based on the tracer principle for imaging. The
radioactive tracer utilized in PET is a compound where
an atom is replaced by a radioisotope or a radioisotope is
added. Only traces of the substance are applied; therefore,
it has no pharmacologic effect in vivo. Typically, the tracer
is a biomolecule that reflects a particular body function
or metabolism. PET tracers can be nonspecific following
a biochemical pathway or allowing for measurement of
tissue extraction or metabolism. These radiotracers include
the glucose analogue fluorine-18-fluorodeoxyglucose (FDG)
which is taken up by high-glucose-utilizing cells, where FDG
is trapped intracellularly by phosphorylation to allow tissue
glucose metabolism assessment. PET tracers can also be spe-
cific radioligands involved in an interaction with receptors.
PET tracer distribution can be quantified in absolute terms
and with dynamic measurement of PET tracer uptake and
distribution kinetic analysis is possible.
In summary, we find that molecular imaging with PET
in most cases will be far superior to molecular imaging with
MRI. In our opinion, optimal utilization of the complemen-
tary information from hybrid PET/MR system will require
a better understanding and foremost a better use of the
pathophysiologic information that can be acquired by MRI.
Simply using the anatomical information in conjunctionwith
themetabolic information from the PET will be a suboptimal
utilization of the potential of the system.
3. Initial Clinical Experience
3.1. Large Animal Model. As compared to preclinical animal
scanners, human hybrid PET/MRI systems can physically
contain larger animals. This opens the opportunity to study
atherosclerosis in human-like atherosclerosis models such as
rabbits and porcines. So far, few feasibility data on this topic
has been published; Dregely et al. [17] presented feasibility
data from 4 high-cholesterol fed rabbits as an abstract at
the 2012 annual meeting of Society of Nuclear Medicine and
Molecular Imaging. Likewise, our institution is working with
a porcine model of atherosclerosis (Figure 2). At our hand,
simultaneous PET/MRI of this large animal model is feasible
but requires some optimization [18].
3.2. Vascular Imaging in Humans without Atherosclerosis.
Our institution recently performed a study aiming at eval-
uating the feasibility of integrated PET/MR imaging of
the carotid arteries in humans [19]. Six HIV patients with
increased risk of atherosclerosis but without any symptoms
of cardiovascular disease were included to a single-FDG-
injection dual-imaging protocol of simultaneous PET/MR
and subsequent integrated PET/CT on the same day. It is
clear from Figure 3 that MR allowed for superior delineation
of both the inner and outer walls of the carotid artery as
compared to the CT in the study. The study found a high
congruence between FDG-uptake quantification using the
two systems despite the inherent methodological differences
between the two systems such as method of attenuation
correction, the use of time-of-flight in PET, and the potential
interference of the MR signal from PET detectors inside the
MR scanner.
3.3. PET/MRI of Human Atherosclerosis in the Carotid Arter-
ies. PET imaging of atherosclerosis has so far focused pri-
marily on FDG. The first report on FDG accumulation in
the large arteries emerged in 2001 [20], and since then, a
large body of evidence has materialized linking FDG uptake
to the macrophage contents of high-risk plaques [21–23].





Figure 3: Comparison of contrast enhanced CT (a) with T1 weighted MRI (b) for vessel delineation in patients without significant carotid
plaque. The right common carotid artery (arrow) and left internal carotid artery (arrowhead) are shown. The bottom row shows fusion with
FDG-PET. This patient was part of a previous published trial [19].
The idea of combining FDG-PET with MRI is not new. In
fact several studies have used sequential PET and MRI for
imaging atherosclerotic plaques in animalmodels [24] as well
as in carotid plaques in humans [25–29]. In our experience
carotid plaque with simultaneous FDG-PET/MRI is feasible
(Figure 4). Future studies will have to show if FDG-PET/MRI
has superior prognostic information as compared to FDG-
PET/CT.
One very interesting trial is the ongoing prospective
observational PESA study [30]. A subgroup of 1,300 partici-
pantswithin this studywhich have evidence of atherosclerosis
on ultrasound or increased coronary artery calcium score
will undergo hybrid FDG PET/MRI study of both the carotid
and iliofemoral arteries and the FDG PET/MRI study will be
repeated at 6 years of followup.
4. Potential Vascular PET/MRI Applications
4.1. New PET Tracers. PET imaging of atherosclerosis has
thus far focused primarily on FDG. A major drawback of
imaging atherosclerosis with FDGPET, however, is the lack of
specificity of the tracer. Another limitation is the high uptake
of FDG in the myocardium, which produces a suboptimal
signal-to-noise ratio when coronary arteries are imaged. As
an alternative, some researchers have suggested 18F-deoxy-
mannose as a more atherosclerosis specific tracer than FDG
[31], but this needs to be confirmed in clinical trials.
A hunt for new and more specific tracers has started. The
tracers should specifically target cell-mediated key molec-
ular processes associated with the vulnerable atheroscle-
rotic plaque. The most prominent of these targets include
macrophage infiltration, apoptosis, hypoxia, and neoangio-
genesis of the intima/media. Activated macrophages express
the somatostatin receptor subtype 2, and this could be
a target for PET imaging. 68Ga-DOTATATE is utilized in
diagnosis and staging of neuroendocrine tumors and has
high affinity for somatostatin receptors and a few studies
have suggested a future role in plaque imaging [32–34]. PET
tracers for imaging apoptosis, hypoxia, and neoangiogenesis
are available, but their use in imaging atherosclerosis is very
limited thus far [35–37].
Another promising PET tracer for plaque imaging is 18F-
sodiumfluoride (NaF).This tracer is deposited by chemisorp-
tions onto hydroxyapatite and is used in oncology to identify
bone metastasis. Recent evidence suggests that NaF uptake
is not equivalent to calcification as identified by CT imaging
[38] but that it can identify “spotty”metabolic active calcifica-
tion in the plaques thought to promote plaque vulnerability.
Using hybrid PET/CT and a retrospective approach, it was
recently described how NaF accumulated in atheroma of
the aorta, iliac, femoral, and carotid arteries [39]; however,
coincidental NaF and FDG uptake (14 of 215 lesions) is rare
[40]. Joshi et al. [41] recently published an interesting study
indicating that NaF PET can identify culprit and ruptured
plaques in patients with recent myocardial infarction.
In summary, we find that the combination of morpho-
logic and functional information from theMRI withmolecu-
lar imaging fromPETmay lead to optimal characterization of
the plaque and thus improved individualized counseling and
therapy.
4.2. Spectroscopy and Hyperpolarization. Image-guided pro-
ton magnetic resonance spectroscopy (1H-MRS) of athero-
sclerotic plaques in carotid arteries using clinical 3-T MR
systems is feasible [42]. The proton spectrum is collected
from image-localized plaques, so that the specific proton







Figure 4: Example of simultaneous acquisition FDG-PET andMRI using biographmMR. (a) MR angiography with severe proximal stenosis
of left internal carotid artery. (b) Fusion of FDG-PET (color) andMRIwith increased FDG-uptake in the internal carotid artery. (c) Transverse
MR showing stenosis of internal carotid artery.
resonances can be identified. Duivenvoorden et al. [42] have
recently used this method to identify liquid phase cholesteryl
ester in carotid plaques. The trial was not without challenges
though. The proton spectra were collected from a voxel of
5 × 5 × 5mm with 13 minutes acquisition time. Only 49% of
the obtained spectra were of adequate quality for analysis. No
studies combining proton spectroscopy with PET have so far
been published in the field of atherosclerosis.
Our institution has recently installed a hyperpolarizer
with our PET/MRI system allowing us to do simultaneous
hyperpolarized MR and PET (HyperPET). Hyperpolariza-
tion of nuclear spins like 13C can increase the MR signal with
a factor of more than 105. Chemical compounds (tracers) like
pyruvate can be enriched with 13C and injected into humans
or animals following ex vivo hyperpolarization.The increased
signal from the 13C allows both imaging and spectroscopy of
the tracerwithin a limited timewindow.HyperpolarizedMRI
for atherosclerosis has only been reported in few preclinical
reports [43]. The HyperPET offers several new applications
for in vivo molecular imaging of atherosclerosis. Due to
its physical nature, PET can only image one radioactive
tracer at the time. In comparison, HyperPET can measure
several biological processes simultaneously; for example,
plaque glycolysis can be assessed with hyperpolarized 13C-
pyruvate and plaque hypoxia can be assessed with a specific
radiolabelled PET tracer like 64Cu-ATSM simultaneously. In
this way, HyperPET can combine two molecular imaging
techniques with a possible synergistic effect in atherosclero-
sis. HyperPET, however, is a very demanding and expensive
solution that will most likely be restricted to experimental
use in few selected cases. Nevertheless, the distinct and
small volume of interest, the plaque, makes HyperPET more
realistic to be applied than in diseases where whole body
evaluation is needed.
4.3. Research Platform. The acquisition of a PET/MRI sys-
tem is a huge task that requires widespread knowhow
by technicians, physicists, and physicians in addition to
extensive funding both initially and for running costs. It is
our expectation that this will limit the technique to mainly
experimental use in a limited number of major university
centers for some time. At our institution, we have set up an
atherosclerosis research workflow in collaboration with the
vascular surgeons (Figure 5). This workflow allows our staff
technicians to become familiar with the multimodality setup,
but at the same time gives us flexibility to introduce new
imaging sequences, reconstructions, or ex vivo molecular
techniques.
One apparent area for simultaneous PET/MRI is cross
validation of new imagingmodalities when similarmolecular
imaging probes exist in PET and MRI. The simultaneous
acquisition allows for experiments to be performed under
one and the same physiologic condition. One very elegant
example is the use of a reporter gene approach. Higuchi
et al. [44] transduced endothelial progenitor cells with the
sodium iodide symporter gene for reporter gene imaging
by PET and also labeled the cells with iron oxides for
visualization by MRI. After intramyocardial injection, cells
were followed with both PET and MRI. The PET tracer
uptake decreased and was undetectable on day 7, whereas
the MRI signal remained unchanged throughout the follow-
up period. Histological analysis confirmed the presence of
labeled transplanted cells at the site on day 1 but not on
day 7, when only iron-loaded macrophages were seen [44].
This example clearly states the difference between anatomical
imaging with MRI and molecular imaging with PET.
4.4. Interventional Studies of Atherosclerosis. Both PET and
MRI have been used for followup after clinical intervention.
The dal-PLAQUE study randomly assigned 130 patients with,
or with high risk of, coronary heart disease to placebo or
dalcetrapib [45]. Coprimary endpoints were MRI-assessed
structural changes in the arterial wall after 24 months and
assessment of arterial inflammation with FDGPET/CT. Also,
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Figure 5: Example of multimodality imaging workflow from our institution.
some animal studies have utilized sequential PET/CT and
MRI as endpoint in interventional trials [46, 47]. There are,
however, clear advantages of using simultaneous PET/MRI as
compared to PET/CT and stand-alone MRI in this setting.
The simultaneous acquisition diminishes the problem with
correct alignment between sequential examinations; this
could be of particular importance in a follow-up trial where
the expected plaque changes might be small. The use of
repetitive CT examinations inflicts a nonnegligible radiation
dose to the patients that is avoided when using MRI.
To date, no interventional studies of human atherosclero-
sis using hybrid PET/MRI have been published.
5. Conclusion
We have presented our initial experiences with simultaneous
PET/MRI in the field of atherosclerosis. It is our belief that
the synergy between PET and MRI will justify its use in
atherosclerotic imaging despite its higher cost and more
complex management. At the same time though, we do not
see a translation from experimental applications to clinical
routine in the very near future.
We expect a continuous development of the integration of
molecular, functional, and anatomical imaging as well as the
clinical indicationswithin atherosclerosis.This novel imaging
methods may lead to early detection of high-risk vulnerable
plaques, enabling clinicians to improve risk stratification and
thus paving the way for individualized therapy.
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